Abdominal radiology (New York) · 2026
Integrated serum metabolomics and MRI biomarkers for MASLD: a practical framework for noninvasive staging and monitoring.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alghzawi Hamzah M, Sahu Sweta, Rana Aditya, Mwita Rhobi, Gundapaneni Sri, Dahiya Dushyant
Аннотация
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in four adults globally, yet early diagnosis remains challenging due to the limitations of current diagnostic modalities. While liver biopsy is the reference standard, its invasiveness limits its utility for population screening. Similarly, single-modality noninvasive tests often fail to distinguish inflammation from fibrosis or detect early metabolic injury. This review synthesized recent evidence (2020-2025) regarding the integration of serum metabolomic profiling with quantitative magnetic resonance imaging (MRI) biomarkers to enhance diagnostic precision.
RESULTS: Emerging data indicate that serum metabolite panels, which detect upstream metabolic dysregulation, are highly complementary to MRI-PDFF (steatosis quantification) and MR Elastography (stiffness/fibrosis measurement). Integrated panels have demonstrated Area Under the Receiver Operating Characteristic (AUROC) values exceeding 0.90 for detecting advanced fibrosis, outperforming individual methods.
CONCLUSIONS: We propose a three-tier clinical framework for integrating these biomarkers: transitioning from simplified biochemical screening in primary care to comprehensive multimodal staging in specialist centers, followed by risk-adapted longitudinal monitoring. This integrated approach offers a pathway toward precision hepatology, enabling earlier intervention and more accurate disease tracking without reliance on invasive procedures.
RESULTS: Emerging data indicate that serum metabolite panels, which detect upstream metabolic dysregulation, are highly complementary to MRI-PDFF (steatosis quantification) and MR Elastography (stiffness/fibrosis measurement). Integrated panels have demonstrated Area Under the Receiver Operating Characteristic (AUROC) values exceeding 0.90 for detecting advanced fibrosis, outperforming individual methods.
CONCLUSIONS: We propose a three-tier clinical framework for integrating these biomarkers: transitioning from simplified biochemical screening in primary care to comprehensive multimodal staging in specialist centers, followed by risk-adapted longitudinal monitoring. This integrated approach offers a pathway toward precision hepatology, enabling earlier intervention and more accurate disease tracking without reliance on invasive procedures.